NIKKEI 225
39,489.46 +316.31 (+0.81%) HANG SENG
17,934.63 -138.27 (-0.77%) CRUDE OIL
80.92 +0.09 (+0.11%) GOLD FUTURES
2,331.50 +0.70 (+0.03%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,855.39 +1,317.58 (+2.77%)
ABBV Jun 2025 185.000 call
- Zacks
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) reachead $170.75 at the closing of the latest trading day, reflecting a -1.15% change compared to its last close.
- Benzinga
AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock
Tuesday, AbbVie Inc (NYSE:ABBV) announced it received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. In its letter, the FDA cited observations identified during the inspection of a third-party manufacturer listed in the New Drug Application (NDA). The inspection at the facility did not involve ABBV-951 or any AbbVie medicine. Also Read: AbbVie’s A
- PR Newswire
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
